Immunotherapy Improves Survival Despite Brain Metastases
Immunotherapy improved median overall survival by 7.5 months regardless of what other treatments patients received.
Diagnosis & Disease Information
Multiple Treatment Modalities for Brain Metastasis in Patients With EGFR-mutant Non-small Cell Lung Cancer
[OncoTargets and Therapy] Management of brain metastases in patients with EGFR-mutant NSCLC is controversial. In this study, researchers find combination and sequential treatment with EGFR-TKIs, chemotherapy, and radiotherapy is beneficial.
Durable Response Achieved With Nivolumab in Untreated Melanoma Brain Metastases
In this phase 2 study, researchers randomly assigned 79 patients with immunotherapy-naive melanoma with brain metastases to receive either nivolumab plus ipilimumab or nivolumab alone.
Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain
Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.
Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis
A retrospective analysis presented at 2017 SABCS reveals the factors that indicate a higher risk of developing brain metastases for women with HER2+ breast cancer.
Overall Survival Increase for Melanoma Brain Metastases
Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months in the last decade.
Survival Is Better With SRS Than With WBRT for NSCLC or Breast Cancer Metastases to the Brain
Longer survival was achieved with stereotactic radiosurgery (SRS) alone than with whole-brain radiation therapy (WBRT) in patients with fewer than 4 brain metastases from NSCLC or breast cancer.
Ceritinib Benefits Patients with ALK-positive NSCLC and Brain Metastases
In patients previously treated with crizotinib for ALK-positive NSCLC and brain metastases, ceritinib treatment elicited clinically meaningful whole-body and intracranial responses with an acceptable tolerability profile.
First-line Afatinib Benefits Lung Cancer Patients With Brain Metastases
For patients with non-small cell lung cancer who have EGFR mutations and brain metastases, progression-free survival was improved with afatinib compared to chemotherapy.
Radiosurgery and Careful Monitoring Combo Recommended for Newly Diagnosed Brain Metastases
Radiosurgery and close monitoring is recommended to better preserve cognitive function in newly diagnosed brain metastases.
- Loading...
Loading...
Next post in ASCO 2015 Annual Meeting
Loading... 
Loading...